Programme - Wilsede Meeting 2023

Programme Wilsede Meeting 2023

Saturday
June 24, 2023

Sunday
June 25, 2023

Monday
June 26, 2023

Tuesday
June 27, 2023

Saturday
June 24, 2023

Sunday
June 25, 2023

Monday
June 26, 2023

Tuesday
June 27, 2023

Important dates

January 2023
Start Abstract submission
February 13, 2023
Start Applicaton for Registration and
Start Stipend Application

March 31, 2023
Abstract submission deadline
March 31, 2023
Stipend application deadline

April 30, 2023
Abstract submission deadline (for Accepted Speakers)

June 24-27, 2023
XXIII. Wilsede-Meeting

Downloads

Local Organising committee and Scientific Contact

Prof. Dr rer. nat Boris Fehse
Prof. Dr med. Dr h.c. Nicolaus Kröger
Universitätsklinikum Hamburg-Eppendorf
Clinic for Stem Cell Transplantation
Research Department Cell and Gene Therapy
Martinistrasse 52, Campus Forschung (N27)
20246 Hamburg

Meeting Office/Contact

Goernestraße 30
20249 Hamburg

9:00-13:00	Registration at University Medical Centre Hamburg-Eppendorf (UKE), Campus Lehre, N55/ Wilsede
16:30-16:40	Welcome Address Boris Fehse & Nicolaus Kröger, Hamburg/DE
16:40-17:55	Session I: Myeloid neoplasia Chairs: Nicolaus Kröger, Hamburg/DE
16:40-17:05	Detangling the fibrosis-driving cross-talk of hermatopoetic cells and their regulating microenvironment in MPN Rebekka Schneider-Kramann, Aachen/DE
17:05-17:30	Deconvoluting microenvironmental interactions for improved prognosis and therapy response in MPN Simon Mendez-Ferrer, Cambridge /UK
17:30-17:45	*Targeting metabolic dependencies in myeloproliferative neoplasm (short talk)* Nageswara Rao Tata, St. Gallen /SUI
18:00-18:45	Special Lecture Chair: Boris Fehse, Hamburg/DE
	Mapping complex organs using single-cell genomics Rafael Kramann, Aachen/DE
19:30	Welcome Reception and Dinner Wilseder Hof

09:00-10:30	Session II: Stem cells in homeostasis and disease I Chairs: Rebekka Schneider-Kramann, Aachen/DE, Ulrich G. Steidl, New York/ USA
09:00-09:25	Impact of Hypomethylating Agents on Mutant HSCs and Blood Production in MDS and CMML John Pimanda, Sidney/AUS
09:25-09:50	The dynamic bone marrow response to inflammatory stress Marieke Essers, Heidelberg /DE
09:50-10:15	Investigating the clonal dynamics underpinning normal and pre-leukaemic haematopoiesis under homeostasis and inflammation Dominique Bonnet, London/UK
10:15-10:30	Notch signalling mediates metabolic changes in AML-associated mesenchymal stem cells (*short talk*) Helal Ahmed, Lübeck & Münster /DE
10:30-11:00	break
11:00-12:55	Session III: Immunotherapy I Chairs: Christos Georgiadis, London /UK; Catherine Bollard, Washington DC /USA
11:00-11:25	CAR-T cell therapy becomes CHIC: „Cytokine Help Intensified CAR“ T cells Hinrich Abken, Regensburg /DE
11:25-11:50	T cell therapies for lymphoma: Broadening applicability Catherine Bollard, Washington DC /USA [DG-GT Keynote]
11:50-12:15	Home brewn CAR-T cells – Update of the HD-CAR-1 trial Michael Schmitt, Heidelberg /DE
12:15-12:40	CAR-T cells -in myeloma Francis Ayuk, Hamburg /DE
12:40-12:55	Single and Combinational Multiplex Base-Edited ‘Universal’ CAR T Cells in a Humanised Model of Primary CD7+CD33+ AML (*short talk*) Arnold Kloos, Hannover /DE
12:55-14:15	Lunch (Heidemuseum) & Poster viewing
14:15-15:45	Session IV: CANCEROMICS and new targets Chairs: John Pimanda, Sidney/AUS; Sonja Loges, Heidelberg/DE
14:15-14:40	Hunting for the oncogenes on chromosome 21 Jan-Henning Klusmann, Frankfurt a.M. /DE
14:40-15:05	The antigen receptor as target for cellular therapies in lymphomas Mascha Binder, Basel/ SUI
15:05-15:30	TCL1 and active RANK cooperate to induce multiple myeloma in mice Maike Buchner, Munich/DE (Max-Eder programme)
15:30-15:45	A20 haploinsufficiency disturbs immune homeostasis and drives the malignant transformation of lymphocytes with permissive antigen receptors (*short talk*) Christoph Schultheiß, Halle/S. /DE
15:45-16:15	break
16:15-17:00	Special Lecture Chairs: Carol Stocking, Hamburg /DE
	Gene therapy for a small but sound goal: the inner ear Axel Schambach, Hannover/ DE
17:00-19:00	POSTER SESSION I (Biology of solid tumours & leukaemia)
19:00	Barbecue „Emhoff“

09:00-10:30	Session II: Stem cells in homeostasis and disease I Chairs: Rebekka Schneider-Kramann, Aachen/DE, Ulrich G. Steidl, New York/ USA
09:00-09:25	1. Impact of Hypomethylating Agents on Mutant HSCs and Blood Production in MDS and CMML John Pimanda, Sidney/AUS
09:25-09:50	2. The dynamic bone marrow response to inflammatory stress Marieke Essers, Heidelberg /DE
09:50-10:15	3. Investigating the clonal dynamics underpinning normal and pre-leukaemic haematopoiesis under homeostasis and inflammation Dominique Bonnet, London/UK
10:15-10:30	4. Notch signalling mediates metabolic changes in AML-associated mesenchymal stem cells (*short talk*) Helal Ahmed, Lübeck & Münster /DE
10:30-11:00	break
11:00-12:30	Session III: Immunotherapy I Chairs: Christos Georgiadis, London /UK; Catherine Bollard, Washington DC /USA
11:00-11:25	1. CAR-T cells in Hamburg Francis Ayuk, Hamburg /DE
11:25-11:50	2. T cell therapies for lymphoma: Broadening applicability Catherine Bollard, Washington DC /USA
11:50-12:15	3. Home brewn CAR-T cells – Update of the HD-CAR-1 trial Michael Schmitt, Heidelberg /DE
12:15-12:30	4. Role of CD39 and TIGIT in proliferation, activation and cytotoxicity of CD8+ T cells in ovarian cancer (*short talk*) Marius Witt, Hamburg /DE
12:30-12:45	5. Single and Combinational Multiplex Base-Edited ‘Universal’ CAR T Cells in a Humanised Model of Primary CD7+CD33+ AML (*short talk*) Arnold Kloos, Hannover /DE
12:45-14:15	Lunch (Heidemuseum) & Poster viewing
14:15-15:45	Session IV: CANCEROMICS and new targets Chairs: John Pimanda, Sidney/AUS; Sonja Loges, Heidelberg/DE
14:15-14:40	1. Hunting for the oncogenes on chromosome 21 Jan-Henning Klusmann, Frankfurt a.M. /DE
14:40-15:05	2. The antigen receptor as target for cellular therapies in lymphomas Mascha Binder, Basel/ SUI
15:05-15:30	3. TCL1 and active RANK cooperate to induce multiple myeloma in mice Maike Buchner, Munich/DE (Max-Eder programme)
15:30-15:45	4. A20 haploinsufficiency disturbs immune homeostasis and drives the malignant transformation of lymphocytes with permissive antigen receptors (*short talk*) Christoph Schultheiß, Halle/S. /DE
15:45-16:15	break


17:00-19:00	POSTER SESSION I (Biology of solid tumours & leukaemia)
19:00	Barbecue „Emhoff“

09:00-10:30	Session V: Immunotherapy II – CARevolution in the clinics Chairs: Francis Ayuk, Hamburg /DE; Hinrich Abken, Regensburg /DE
09:00-09:25	CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial Liane Preußner, Mainz /DE
09:25-09:50	Base-Edited ‘universal’ CAR7 T Cells for relapsed T-cell Acute Lymphoblastic LeukaemiaChristos Georgiadis, London /UK
09:50-10:15	CAR-T cells for the treatment of B-cell mediated autoimmune diseasesAndreas Mackensen, Erlangen /DE
10:15-10:30	Role of CD39 and TIGIT in proliferation, activation and cytotoxicity of CD8+ T cells in ovarian cancer (short talk) Marius Witt, Hamburg /DE
10:30-11:00	break
11:00-12:30	Session VI: Epigenetics and cancer Chairs: Maike Buchner, Munich/DE; Daniel G. Tenen, Singapore /SG
11:00-11:25	Plasticity of cancer cells is induced by ribosomal RNA modifications Carsten Müller-Tidow, Heidelberg /DE
11:25-11:50	Smiley, a novel DNA methylation sensitive element regulating gene expression in tumor suppressors and oncogenes Dan Tenen, Singapore /SG
11:50-12:15	Deep learnign for Hi-C reveals coherence between enhancer states and chromosome conformation in T dell differenitation Matthias Merkenschlager, London /UK
12:15-12:30	Career Development Programme of German Cancer Aid Matthias Serwe, Bonn/DE
12:30-13:30	Lunch (Heidemuseum) & Poster viewing
13:30-15:30	Session VII: Gene therapy Chairs: Boris Fehse, Hamburg /DE; Andreas Mackensen, Erlangen/DE
13:30-13:55	Gene therapy for hematopoietic inherited disorders: twenty years of progress Marina Cavazanna, Paris /FR
13:55-14:20	HSC gene editing in macaques: assessing risks and creating disease models Cynthia Dunbar, Washington DC /USA
14:20-14:35	Long term lineage commitment is modulated by the underlying disease in hematopoietic stem cell gene therapy patients (*short talk*) Eugenio Montini, Milano /IT
14:35-14:50	Advancing the translation of CAR-T cell therapies for HIV-positive patients (*short talk*) Lea Isabell Schwarze, Hamburg/DE
14:50-15:05	Intrathymic AAV delivery results in therapeutic site-specific integration at TCR loci (*short talk*) Daniela Cesana, Milano /IT
15:05-15:30	break
15:30-17:00	Session VIII: HSC biology & transplantation Chairs: Ruud Delwel, Rotterdam /NL; Cynthia Dunbar, Washington DC /USA
15:30-15:55	Pre-leukemia bone marrow failure syndrome – from understanding the mechanisms to advanced therapies Yulia Skokowa, Tübingen /DE
15:55-16:20	A HOXB4-initiated and -dependent myeloid leukaemia: implications for origin and targeted cure of clonal proliferative disease Norman Iscove, Toronto /CAN
16:20-16:45	Functional heterogeneity of leukemia stem cells in vivo Irmela Jeremias, Munich/ DE
16:45-17:00	CRISPR-based transcriptional haematopoietic stem cell editing for enhanced anti-leukaemic graft function (*short talk*) Franziska Baatz, Hannover /DE
17:00-19:00	POSTER SESSION II (Gene and Immunotherapy, OMICs & Targeted therapies, Others)
19:00	Farewell Barbecue – „Emhoff“

09:00-10:05	Session IX: Leukaemia & lymphoma Chairs: Carsten Müller-Tidow, Heidelberg /DE; Britta Will, New York /USA
09:00-09:25	Identification and targeting of oncogenic transcriptional networks in MLLr B-cell acute lymphoblastic leukaemia Anjali Cremer, Frankfurt a.M. /DE (Max-Eder Programme)
09:25-09:50	Understanding and Targeting Transcription Factor Dynamics in Normal and Malignant Haematopoiesis Ulrich G. Steidl, New York /USA
09:50-10:05	Targeting functional dependencies in T-cell lymphoma Raphael Koch, Göttingen /DE (Max-Eder Programme)
10:05-10:30	break
10:30-12:00	Session X: Stem cells in homeostasis and disease II Chairs: Anjali Cremer, Frankfurt a.M./DE Yulia Skokowa, Tübingen /DE
10:30-10:55	How to switch off Evil enhancers in AML Ruud Delwel, Rotterdam /NL
10:55-11:20	AML -derived extracellular vesicles (EV) contains DNA-protein complex that alter bone marrow mesenchymal stem cells (BM-MSC) by inducing non-mutational dysfunction of p53 Basant Kumar Thakur, Essen /DE
11:20-11:45	An iron rheostat controls hematopoietic stem cell function Britta Will, New York /USA
11:45-12:00	Closing remarks
12:00	Departure (packed Lunch)

XXIII. Wilsede Meeting on Modern Trends in Human Leukaemia and Cancer June 24-27, 2023 - Wilsede, Germany

Programme Wilsede Meeting 2023

XXIII. Wilsede Meeting on
Modern Trends in Human Leukaemia and Cancer
June 24-27, 2023 - Wilsede, Germany